To further determine risk of prostate cancer, combination of prostate-specific antigen with single nucleotide polymorphisms was shown to be effective in men with prostate-specific antigen levels greater than 4 ng/mL [50]. The gene discussed is KLK3; the disease is prostate carcinoma.